These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 36986665)

  • 1. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?
    Rusu A; Munteanu AC; Arbănași EM; Uivarosi V
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential new fluoroquinolone treatments for suspected bacterial keratitis.
    Herbert R; Caddick M; Somerville T; McLean K; Herwitker S; Neal T; Czanner G; Tuft S; Kaye SB
    BMJ Open Ophthalmol; 2022 Jul; 7(1):. PubMed ID: 36161851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Knowledge Regarding Safety Profile, Use, and Boxed Warnings of Fluoroquinolones Among Healthcare Professionals in Saudi Arabia: A Potential Implication for Drug Regulatory Authorities.
    Mallhi TH; Alanazi AS; Khan YH; Alotaibi NH; Salman M; Alzarea AI; Khan SU; Alruwaili NK; Alenazi AS; Alatawi AD; Iqbal Z; Butt MH; Iqbal MS
    Front Med (Lausanne); 2022; 9():816320. PubMed ID: 35572979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of healthcare professionals' understanding of fluoroquinolones' safety profile, usage, and boxed warnings in Pakistan.
    Abbas M; Kashmiri K; Rehman IU; Ali Z; Rahman AU; Khalil A; Ming LC; Shafique M; Khan TM
    J Pharm Policy Pract; 2023 Nov; 16(1):154. PubMed ID: 38012805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.
    Rusu A; Lungu IA; Moldovan OL; Tanase C; Hancu G
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials.
    Tandan M; Cormican M; Vellinga A
    Int J Antimicrob Agents; 2018 Nov; 52(5):529-540. PubMed ID: 29702230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles.
    Sousa J; Alves G; Fortuna A; Falcão A
    Curr Drug Saf; 2014; 9(2):89-105. PubMed ID: 24410307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of antibacterial-like activity on a silica surface: fluoroquinolones and their environmental metabolites.
    Lewis G; Juhasz A; Smith E
    Environ Sci Pollut Res Int; 2011 Aug; 19(7):2795-801. PubMed ID: 22311580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative Properties of 7,8-Ethylene Diamine Chelator-Lipophilic Fluoroquinolone Derivatives Against Colorectal Cancer Cell Lines.
    Khaleel S; Al-Hiari Y; Kasabri V; Haddadin R; Albashiti R; Al-Zweri M; Bustanji Y
    Anticancer Agents Med Chem; 2022; 22(5):1012-1028. PubMed ID: 34165411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delafloxacin: A Review in Community-Acquired Pneumonia.
    Lee A; Lamb YN; Shirley M
    Drugs; 2022 Jun; 82(8):913-923. PubMed ID: 35708893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate use of fluoroquinolones in children.
    Principi N; Esposito S
    Int J Antimicrob Agents; 2015 Apr; 45(4):341-6. PubMed ID: 25726705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,762 clinical isolates obtained from 69 centers in 2013].
    Yamaguchi K; Tateda K; Ohno A; Ishii Y; Murakami H
    Jpn J Antibiot; 2016 Feb; 69(1):1-25. PubMed ID: 27290827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is EMA warning on quinolones and fluoroquinolones really assessed? An EudraVigilance database analysis.
    DE Nunzio C; Nacchia A; Lombardo R; Franco A; Cicione A; Trucchi A; Labella M; Bartoletti R; Simonato A; Ficarra V; Tubaro A
    Minerva Urol Nephrol; 2023 Jun; 75(3):374-380. PubMed ID: 36940165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Bassetti M; Hooper D; Tillotson G
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S233-S240. PubMed ID: 30957169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
    Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
    Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.